Sol-Gel Technologies Ltd. NCM · SLGL
Price alert —
Sign in to get a one-time email the moment SLGL crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · SLGL
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.0B | $-0.0B | — | -3450.9% | -3569.4% |
| 2025-12-31 | $0.0B | $-0.0B | $-0.0B | — | -429.2% | -490.1% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | — | -1485.5% | -1572.0% |
| 2025-06-30 | $0.0B | $0.0B | $0.0B | — | 67.3% | 65.1% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.0B | — | -854.3% | -879.6% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare SLGL vs peers
Line SLGL up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with SLGL
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-28 | -1.31 | -2.86 | +54.2% | -1.9% |
| 2026-03-19 | -1.06 | 0.39 | -371.8% | -10.7% |
| 2025-11-20 | -2.13 | -2.09 | -1.9% | +2.5% |
| 2025-08-15 | 4.17 | -0.70 | +695.7% | +4.3% |
| 2024-11-15 | -0.10 | -0.50 | +80.0% | -5.2% |
| 2024-08-16 | 0.70 | -1.90 | +136.8% | +9.1% |
| 2024-05-20 | -2.30 | -1.60 | -43.8% | +13.5% |
| 2024-03-13 | -1.70 | -1.75 | +2.9% | -0.5% |
| 2023-11-09 | -2.10 | -2.30 | +8.7% | -7.4% |
| 2023-08-10 | -2.20 | -2.55 | +13.7% | -9.7% |
| 2023-05-12 | -4.10 | -2.15 | -90.7% | +0.6% |
| 2023-03-10 | -2.50 | -1.25 | -100.0% | -4.1% |
| 2022-11-10 | -1.50 | -0.65 | -130.8% | -1.8% |
| 2022-08-04 | -0.10 | -0.97 | +89.7% | +3.8% |
| 2022-05-13 | -2.40 | -2.90 | +17.2% | +0.0% |
| 2022-03-30 | 6.10 | 4.45 | +37.1% | -6.3% |
| 2021-11-12 | 0.50 | -3.30 | +115.2% | +0.1% |
| 2021-08-04 | -3.50 | -1.83 | -90.9% | +2.4% |
| 2021-05-13 | -1.80 | -4.57 | +60.6% | — |
| 2021-03-04 | -2.80 | -4.10 | +31.7% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| SLGL ★ | $0B | — | -10.3 | 14.9 | -105.0 | 5.4 | 9.3% | -89.5% | — | — |
| LLY | $1,037B | 41.4 | 25.9 | — | 30.0 | 33.3 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $392B | 32.5 | 19.2 | 0.9 | 18.1 | 3.7 | 19.5% | 0.4% | 61.5% | 5.81% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 35.9 | 13.2 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $448B | 123.6 | 15.6 | 7.1 | 17.2 | -67.2 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $141B | 18.9 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.75% |
| TMO | $196B | 29.0 | 19.3 | — | 20.8 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 43.67%
| Holder | Shares | % out |
|---|---|---|
| Opaleye Management Inc. | 500,000 | 17.79% |
| Great Point Partners LLC | 274,363 | 9.76% |
| Phoenix Financial Ltd. | 210,849 | 7.50% |
| Trails Edge Capital Partners, LP | 85,496 | 3.04% |
| Citadel Advisors Llc | 37,145 | 1.32% |
| Affinity Asset Advisors, Llc | 35,000 | 1.25% |
| Squadron Capital Management LLC | 31,000 | 1.10% |
| Stonepine Capital Management, LLC | 27,778 | 0.99% |
| Yelin Lapidot Holdings Management Lt | 17,753 | 0.63% |
| Xtx Topco Ltd | 8,010 | 0.29% |
Insider activity · 90d
7 buys / 0 sells · ratio 7.0 · Finnhub
- Opaleye Management Inc. BUY 492,241 @ $73.95
- Opaleye Management Inc. BUY 492,012 @ $73.69
- Opaleye Management Inc. BUY 491,712 @ $71.97
- Opaleye Management Inc. BUY 490,312 @ $71.99
- Opaleye Management Inc. BUY 490,000 @ $64.43
- Opaleye Management Inc. BUY 488,437 @ $66.87
- Opaleye Management Inc. BUY 486,500 @ $67.98
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-15 | 4 | view · |
| 4 | 2026-07-10 | 4 | view · |
| 4 | 2026-07-02 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-14 | 4 | view · |
| 4 | 2026-03-24 | 4 | view · |
| 4 | 2026-02-18 | 4 | view · |
| 4 | 2026-02-04 | 4 | view · |
| 4 | 2026-01-29 | 4 | view · |
| 4 | 2026-01-23 | 4 | view · |
| 4 | 2026-01-06 | 4 | view · |
| 4 | 2025-12-31 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-29 | 4 | view · |
| 4 | 2025-12-19 | 4 | view · |
| 4 | 2025-12-16 | 4 | view · |
| 4 | 2025-12-09 | 4 | view · |
| 4 | 2025-12-03 | 4 | view · |
| 4 | 2025-11-26 | 4 | view · |
| 4 | 2025-11-21 | Insider transaction (Form 4) | view · |
About SLGL
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Options picks · SLGL
ITM + OTM ideas from the latest scanLoading…
Congress trades · SLGL
STOCK Act disclosuresLoading…
SEC filings & insiders · SLGL
EDGAR · liveLoading…
Holders · SLGL
Institutions & insider activityLoading…